Insulin-Like Growth Factor-1 and Anti-Vascular Endothelial Growth Factor in Retinopathy of Prematurity: Has the Time Come
MetadataShow full item record
CitationStahl, Andreas, Ann Hellstrom, and Lois E.H. Smith. 2014. Insulin-Like Growth Factor-1 and Anti-Vascular Endothelial Growth Factor in Retinopathy of Prematurity: Has the Time Come. Neonatology 106, no. 3: 254–260. doi:10.1159/000365132.
AbstractTreatment of ROP is currently evolving. Novel therapeutic options are emerging that have the potential to complement existing therapies and improve treatment outcomes. However, any new therapeutic options must be thoroughly evaluated before existing (and successful) treatment paradigms can be amended. This is particularly so when switching from locally effective therapies like photablative laser therapy to systemic pharmacologic treatments that may have hitherto unknown widespread side effects. This review compiles the current knowledge of where and when the two most advanced pharmacologic treatment options for ROP, IGF-1 supplementation and anti-VEGF treatment, may have their place in future therapy regimens for ROP. The requirement for clinical studies is emphasized: these are needed to address safety considerations before any of these interventions can achieve the status of standard clinical care in the very vulnerable population of ROP infants.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:33776188
- HMS Scholarly Articles